Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting c-Myb expression in human disease.

Robert G Ramsay1, Anna L Barton, Thomas J Gonda

  • 1Differentiation and Transcription Group, Trescowthick Laboratories, Peter MacCallum Cancer Institute, Victoria, Australia. r.ramsay@pmci.unimelb.edu.au

Expert Opinion on Therapeutic Targets
|April 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.

Blood advances·2025
Same author

The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids.

Journal of medicinal chemistry·2025
Same author

CREB: A multifaceted transcriptional regulator of neural and immune function in CNS tumors.

Brain, behavior, and immunity·2023
Same author

Technological advances define shifting pathway signaling from normal to primary and metastatic colorectal cancer.

Growth factors (Chur, Switzerland)·2023
Same author

National recommendations to standardise acute kidney injury detection and alerting.

Annals of clinical biochemistry·2023

The transcription factor c-Myb is crucial for normal development and survival in hematopoietic and gastrointestinal systems. Blocking c-Myb with oligodeoxynucleotides (ODNs) shows promise for treating various cancers.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • c-Myb is a transcription factor vital for hematopoietic and gastrointestinal development, regulating cell division, differentiation, and survival.
  • Dysregulated c-Myb expression is implicated in leukemias and epithelial cancers, promoting progression and metastasis by activating genes like COX-2, Bcl-2, and c-Myc.
  • Mice lacking functional c-myb die in utero, highlighting its essential developmental role.

Purpose of the Study:

  • To review the clinical potential of blocking c-Myb expression in malignancies.
  • To explore the strategic use of oligodeoxynucleotides (ODNs) for anti-c-Myb therapies in vivo.
  • To discuss the application of these therapies beyond hematopoietic malignancies.

Main Methods:

  • Review of preclinical and clinical data on c-Myb's role in cancer.

Related Experiment Videos

  • Evaluation of nuclease-resistant oligodeoxynucleotides (ODNs) as therapeutic agents.
  • Analysis of gene targets regulated by c-Myb in cancer progression.

    • Main Results:

    • Strong preclinical data support the clinical potential of blocking c-Myb in malignancies.
    • ODNs are emerging as acceptable therapeutic reagents with tolerable toxicities and delivery methods.
    • c-Myb influences angiogenesis, proliferation, and apoptosis through target genes like COX-2, Bcl-2, and c-Myc.

    Conclusions:

    • Anti-c-Myb therapies, particularly using ODNs, hold promise for treating a spectrum of cancers, including non-hematopoietic malignancies.
    • Further optimization of ODN efficacy, toxicity, and delivery is necessary.
    • Combination therapies involving anti-c-Myb agents and established cytotoxic or differentiation-inducing drugs are likely to be most successful.